Skip to main content
SRZN
NASDAQ Life Sciences

Director and 10% Owner Tim Kutzkey Buys $300K in SRZN Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$19.06
Mkt Cap
$163.371M
52W Low
$5.9
52W High
$24.94
52W Position info
223% above low
Off High info
24% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9 on light trading volume (0.2× avg).

Summary

Tim Kutzkey, a Director and 10% owner of Surrozen, Inc., made an open market purchase of $300,297 worth of company stock.


Key Events · Ownership and Investor Activity · SRZN

  • Significant Insider Purchase

    Director and 10% owner Tim Kutzkey acquired 15,100 shares of Surrozen, Inc. common stock for a total value of $300,297.

  • Indirect Ownership

    The shares were purchased indirectly through The Column Group III, LP and The Column Group III-A, LP, where Mr. Kutzkey serves as a managing partner.

  • Positive Signal

    This transaction indicates continued conviction from a key stakeholder and board member, potentially boosting investor sentiment.


Analysis · SRZN · Life Sciences

This significant open market purchase by a Director and 10% owner signals strong confidence in Surrozen's future prospects. While the purchase was made indirectly through investment funds where Mr. Kutzkey is a managing partner, his position on the board adds weight to this investment. Such an insider buy can be interpreted by the market as a positive indicator, suggesting that those closest to the company see value at current levels.

How filings like this one have moved

In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $19.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.4M. The 52-week trading range was $5.90 to $24.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Oct 02, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $29.72 info
Change: -$0.410 (-1%) info
Market Cap: $349.316M info
SRZN
Oct 02, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $29.72 info
Change: -$0.410 (-1%) info
Market Cap: $349.316M info
SRZN
Sep 24, 2026, 11:41 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $31.51
Real-time Price: $29.72 info
Change: -$1.79 (-6%) info
Market Cap: $349.316M info
SRZN
May 18, 2026, 6:49 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $28.15
Real-time Price: $29.72 info
Change: +$1.57 (+6%) info
Market Cap: $349.316M info
SRZN
May 06, 2026, 4:49 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $34.13
Real-time Price: $29.72 info
Change: -$4.41 (-13%) info
Market Cap: $349.316M info